No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CMPS240517C10000
- 0.01
- -0.04-80.00%
15min DelayClose May 15 16:00 ET
0.05High0.01Low
0.05Open0.05Pre Close29 Volume922 Open Interest10.00Strike Price91.00Turnover130.89%IV20.89%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.01Time Value100Contract SizeAmericanOptions Type0.0322Delta0.0878Gamma828.00Leverage Ratio-0.0091Theta0.0000Rho26.67Eff Leverage0.0005Vega
Intraday
- 5D
- 1D
News
COMPASS Pathways Plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter
Earnings Call Summary | COMPASS Pathways(CMPS.US) Q1 2024 Earnings Conference
The following is a summary of the COMPASS Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript:Financial Performance:COMPASS Pathways had a net cash usage in operations of $20.8 million in Q1 2024 and
COMPASS Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical Trials
Comments
$COMPASS Pathways(CMPS.US$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
$COMPASS Pathways(CMPS.US$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.
Gainers:
• $Genco Shipping & Trading(GNK.US$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US$ +3.7% (pr...
• $Genco Shipping & Trading(GNK.US$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US$ +3.7% (pr...
21
Read more